Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Palisade Bio, Inc. (PALI)

1.9800 -0.0100 (-0.50%)
As of 9:48:57 AM EDT. Market Open.
Trade PALI on Coinbase
Chart Range Bar
Loading chart for PALI
  • Previous Close 1.9900
  • Open 2.0100
  • Bid 1.9000 x 100
  • Ask 2.0000 x 100
  • Day's Range 1.9701 - 2.0300
  • 52 Week Range 0.5300 - 2.8600
  • Volume 67,951
  • Avg. Volume 2,833,225
  • Market Cap (intraday) 345.056M
  • Beta (5Y Monthly) 1.54
  • PE Ratio (TTM) 3.05
  • EPS (TTM) 0.6500
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 10.22

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

www.palisadebio.com

14

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PALI
15.74%
S&P 500 (^GSPC)
12.71%

1-Year Return

PALI
204.62%
S&P 500 (^GSPC)
19.65%

3-Year Return

PALI
80.00%
S&P 500 (^GSPC)
70.85%

5-Year Return

PALI
99.90%
S&P 500 (^GSPC)
70.11%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings -8.9M
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

-8M
-6M
-4M
-2M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

5.00
10.22 Average
1.9800 Current
25.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 7/23/2026
Analyst Oppenheimer
Rating Action Initiated
Rating Outperform
Price Action Announces
Price Target 8

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    341.96M

  • Enterprise Value

    208.65M

  • Trailing P/E

    3.02

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    621.46

  • Price/Book (mrq)

    2.81

  • Enterprise Value/Revenue

    417.30

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -32.98%

  • Return on Equity (ttm)

    -51.37%

  • Revenue (ttm)

    500k

  • Net Income Avi to Common (ttm)

    -31.94M

  • Diluted EPS (ttm)

    0.6500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    125.17M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -8.65M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

1.9800 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: